ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 874

Comparative Analysis Between ANCA-associated Interstitial Lung Disease and Interstitial Pneumonitis with Autoimmune Features

Iazsmin Ventura1, Anisha Dua 2, Ayodeji Adegunsoye 3, Mary Strek 3, James Curran 1, Alexandra Weiss 1 and Jonathan Chung 1, 1University of Chicago, Chicago, 2Northwestern University Feinberg School of Medicine, Chicago, IL, 3University of Chicago, Department of Pulmonary and Critical Care, Chicago

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: ANCA, CALIPER and survival, interstitial lung disease, IPAF

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S085: Vasculitis – ANCA-Associated I (869–874)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) have been identified in patients who have pneumonia without a diagnosis of ANCA-associated vasculitis (AAV). These patients are presently categorized as having idiopathic pulmonary fibrosis (IPF). Recent criteria categorize patients with features of autoimmunity but without a defined connective tissue disease as having interstitial pneumonitis with autoimmune features (IPAF). However, these criteria do not include ANCA. Growing evidence suggests that patients with ILD and ANCA may present differently from those with ILD in the setting of AAV or IPF.

Methods: We performed a retrospective case-cohort study of ANCA-associated ILD and randomly selected age and gender-matched controls with IPAF. Both groups were followed at the University of Chicago (1/2005 – 10/2018). Data on autoimmune serologies, baseline high-resolution CT scan using CALIPER (Computer-Aided Lung Informatics for Pathology Evaluation and Rating) parameters, baseline and longitudinal pulmonary functional tests (PFTs), vital status and lung transplant were collected from the electronic medical records. Variable comparisons utilized the Student’s t-test or chi-squared, while panel data was evaluated with mixed-effect modeling. Survival analysis was computed using Cox regression models and the Kaplan-Meier estimator. (IRB#18-03349; #14163-A).

Results: In the study population (ANCA-associated ILD, n=52; IPAF, n=101), the mean age at ILD diagnosis was 63yrs, and 59% were women. Compared to white subjects, racial/ethnic minorities had lower TLC%, FVC%, FEV1%, and DLCO% (P=0.004, 0.003, 0.011, and 0.08 respectively). Groups were otherwise comparable with respect to race (Table 1). The prevalence of other autoimmune antibodies appeared greater in ANCA-associated ILD compared to IPAF, however these differences were not statistically significant (Table 1). Baseline and longitudinal PFTs were similar between both groups. Patients with ANCA-associated ILD had greater honeycombing in central portions of the lower lobes, and the central region of the left middle lobe (Table 2). ANCA positivity was not predictive of mortality (Figure 1), whereas total lung vessel volume, older age, non-White race, and lower DLCO% (P=0.043, < 0.001, 0.008, 0.054 respectively) were associated with mortality.

Conclusion: This is the largest US study comparing ANCA-associated ILD to IPAF. Our results suggest that these groups are similar, and these findings may argue in favor of adding ANCA to the IPAF criteria. Our radiographic data also suggests that ANCA-associated ILD may be driven by inhaled antigens and airway inflammation, leading to centrilobular fibrosis.


Table 1 – Demographic -serology – PFTS


Table 2 – Cox analysis


Figure 1 – Kaplan-Meier


Disclosure: I. Ventura, None; A. Dua, None; A. Adegunsoye, Boehringer Ingelheim, 2, 5, 8, Pulmonary Fibrosis Foundation, 2, American College of Chest Physicians, 2; M. Strek, Boehringer Ingelheim, 2, 5, Novartis, 2; J. Curran, None; A. Weiss, None; J. Chung, None.

To cite this abstract in AMA style:

Ventura I, Dua A, Adegunsoye A, Strek M, Curran J, Weiss A, Chung J. Comparative Analysis Between ANCA-associated Interstitial Lung Disease and Interstitial Pneumonitis with Autoimmune Features [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/comparative-analysis-between-anca-associated-interstitial-lung-disease-and-interstitial-pneumonitis-with-autoimmune-features/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-analysis-between-anca-associated-interstitial-lung-disease-and-interstitial-pneumonitis-with-autoimmune-features/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology